TX-MAVENIR
11.1.2021 14:02:37 CET | Business Wire | Press release
Mavenir , the industry’s only end-to-end Network Software Provider and a leader in accelerating software network transformation for communications service providers (CSPs), has expanded and cloudified its Portfolio by announcing four new solutions: WebScale Platform, AI & Analytics, Multi-Access Edge Computing (MEC) and Digital Enablement Platform, all available today.
With cloud-native applications and technology innovation in the software space for mobile communications, consistent with Mavenir’s DNA, these solutions support the ongoing cloudification of the mobile networks, to enable CSPs to meet the growing data demands on their networks.
Mavenir’s cloud centric approach means moving applications to Commercial Off-The-Shelf (COTS) computing servers and embracing a complete ecosystem with applications in the Cloud (private, hybrid or public), which complement the basic Network Virtualized Functions (NVFs) and bring automation to improve the way operators manage and operate their networks.
In addition, this approach creates more flexibility and agility enabling the introduction of new services not only in the traditional consumer business, but also in the enterprise arena.
Webscale Platform: Suresh Somasundaram, SVP of 5G Cloud Platforms at Mavenir explains, “Mobile networks require digital transformation towards webscale platform technology that utilizes open source, Kubernetes platform as a service (PaaS). While a Kubernetes-based platform (PaaS) provides the foundation for fully automated life cycle management, it is built for mainly IT and enterprise applications and requires additional and specialized functions to support telecom and specifically, mobile workloads. To support those types of workloads, Mavenir has developed a common software extending standard opensource PaaS components to support telco needs for webscale deployment and to provide agile delivery of new applications expanding to Performance, Monitoring, Legal Intercept and Security. Mavenir’s WebScale Platform is the solution to give Mobile Operators the webscale agility of the Internet players.”
AI-powered Analytics : Kuntal Chowdhury, GM, AI & Analytics at Mavenir said, “With the cloudification and automation of the telecom networks, it becomes essential to utilize AI & Analytics solutions in a scalable platform combining real-time and big data analytics based on advanced Machine Learning algorithms. Mavenir’s AI & Analytics platform delivers extensive insights that are mandatory for WebScale network automation, slice management, security and many other use cases defined for the MEC (EdgeAI), RAN intelligence, traffic optimization and security. The AI/ML algorithms are defined with Mavenir’s deep telecom domain expertise, while keeping the interfaces standards-compliant & the platform open for collaborative innovation.”
Multi-access Edge Computing (MEC) : Ashok Khuntia, GM Cloud Packet Computing says, “Delivering low latency and high bandwidth at the edge of the network promises many exciting applications in 5G. Mavenir's optimized low-footprint data processing 5G Core platform enables mission critical MEC applications in the areas of Industrial automation, Augmented Reality/Virtual Reality, Gaming, Video surveillance, Autonomous driving and others. The additional focus on Multi-access Edge Computing (MEC) will accelerate such applications for many different industries and sectors.”
Digital Enablement: Sandeep Singh, GM, Digital Enablement at Mavenir noted, “Mavenir enables Operators and Enterprises to launch innovative value-based services faster to market with lower upfront investments in capital and time. Mavenir’s Digital Enablement Platform unlocks any network data, sources partner data, and serves up a value-added offering enriched through the platform’s flexible business control functions like Partner/Customer Management, Order Journey-Experience builder, Subscription/Usage Billing, Charging and Settlement. With the design focus on ‘adaptability’, the platform provides customers the agility and flexibility to experiment iteratively and deliver enhanced subscriber engagement experiences, ultimately benefitting in increased market reach and customer stickiness through new revenue generating services.”
“With a modern and secure Webscale platform as a foundation for edge computing, state of the art AI-based Analytics and Customer engagement solutions in our portfolio, Mavenir is a partner of choice for Telcos looking to offer new mission critical network edge solutions, transform network operations and business models for new 5G networks. In addition, Enterprises who need cost efficiency and customization in their connectivity and communication solutions will benefit,” said Bejoy Pankajakshan, Mavenir’s Chief Strategy Officer. “With a worldwide installed base and decades of experience in designing ‘Multi-G’ Telco services, Mavenir now offers its customer a path to realize the true potential of 5G through these new technology solutions.”
About Mavenir:
Mavenir is the industry's only end-to-end, cloud-native Network Software and Solutions/Systems Integration Provider, focused on accelerating software network transformation for Communications Service Providers (CSPs). Mavenir offers a comprehensive end-to-end product portfolio across every layer of the network infrastructure stack. From 5G application/service layers to packet core and RAN, Mavenir leads the way in evolved, cloud-native networking solutions enabling innovative and secure experiences for end users. Leveraging innovations in IMS (VoLTE, VoWiFi, Advanced Messaging (RCS)), Private Networks as well as vEPC, 5G Core and OpenRAN vRAN, Mavenir accelerates network transformation for more than 250+ CSP customers in over 120 countries, which serve over 50% of the world’s subscribers.
Mavenir embraces disruptive, innovative technology architectures and business models that drive service agility, flexibility, and velocity. With solutions that propel NFV evolution to achieve web-scale economics, Mavenir offers solutions to help CSPs with cost reduction, revenue generation, and revenue protection. mavenir.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005303/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom